Want to see HK:0399 full AI Analyst Report?
Total Valuation
Innovative Pharmaceutical Biotech has a market cap or net worth of HK$231.21M. The enterprise value is HK$1.24B.
Market CapHK$231.21M
Enterprise ValueHK$1.24B
Share Statistics
Innovative Pharmaceutical Biotech has 3,167,207,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,167,207,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Innovative Pharmaceutical Biotech’s return on equity (ROE) is 0.51 and return on invested capital (ROIC) is -1.29%.
Return on Equity (ROE)0.51
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-1.29%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee104.55K
Profits Per Employee-28.52M
Employee Count20
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Innovative Pharmaceutical Biotech is ―. Innovative Pharmaceutical Biotech’s PEG ratio is 0.00220.
PE Ratio―
PS Ratio143.85
PB Ratio-0.44
Price to Fair Value-0.44
Price to FCF-28.50
Price to Operating Cash Flow56.33
PEG Ratio0.00220
Income Statement
In the last 12 months, Innovative Pharmaceutical Biotech had revenue of 2.09M and earned -345.94M in profits. Earnings per share was -0.20.
Revenue2.09M
Gross Profit188.00K
Operating Income-13.26M
Pretax Income-570.35M
Net Income-345.94M
EBITDA-310.25M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was 2.52M and capital expenditures 0.00, giving a free cash flow of 2.52M billion.
Operating Cash Flow2.52M
Free Cash Flow2.52M
Free Cash Flow per Share<0.01
Dividends & Yields
Innovative Pharmaceutical Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change-70.45%
50-Day Moving Average0.07
200-Day Moving Average0.16
Relative Strength Index (RSI)32.26
Average Volume (3m)17.09M
Important Dates
Innovative Pharmaceutical Biotech upcoming earnings date is Nov 27, 2026, TBA (Confirmed).
Last Earnings DateJun 30, 2026
Next Earnings DateNov 27, 2026
Ex-Dividend Date―
Financial Position
Innovative Pharmaceutical Biotech as a current ratio of <0.01, with Debt / Equity ratio of -139.05%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap3.34
Net Debt to EBITDA-3.22
Interest Coverage Ratio-0.05
Taxes
In the past 12 months, Innovative Pharmaceutical Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Innovative Pharmaceutical Biotech EV to EBITDA ratio is -4.19, with an EV/FCF ratio of -123.22.
EV to Sales621.98
EV to EBITDA-4.19
EV to Free Cash Flow-123.22
EV to Operating Cash Flow-123.22
Balance Sheet
Innovative Pharmaceutical Biotech has HK$18.07M in cash and marketable securities with HK$1.09B in debt, giving a net cash position of -HK$1.07B billion.
Cash & Marketable SecuritiesHK$18.07M
Total DebtHK$1.09B
Net Cash-HK$1.07B
Net Cash Per Share-HK$0.34
Tangible Book Value Per Share-HK$0.61
Margins
Gross margin is 14.46%, with operating margin of -634.29%, and net profit margin of -16544.09%.
Gross Margin14.46%
Operating Margin-634.29%
Pretax Margin-27276.23%
Net Profit Margin-16544.09%
EBITDA Margin-14837.25%
EBIT Margin-14837.25%
Analyst Forecast
The average price target for Innovative Pharmaceutical Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―